Syn­log­ic reach­es end of the road for syn­thet­ic bi­ol­o­gy quest af­ter piv­otal da­ta dis­ap­point

Syn­log­ic is clos­ing out its 10-year quest in har­ness­ing syn­thet­ic bi­ol­o­gy to cre­ate new ther­a­pies af­ter de­cid­ing that its lead pro­gram is un­like­ly to suc­ceed in a piv­otal study.

The biotech will cease op­er­a­tions and lay off most of its em­ploy­ees — more than 90% — leav­ing on­ly enough staffers to as­sist in wind­ing down the study. The re­main­ing team will al­so help ex­plore strate­gic al­ter­na­tives, in­clud­ing but not lim­it­ed to M&A, as­set deals or out­right dis­so­lu­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER